Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis

Yoshifumi Ino, Yoshiyuki Arita, Tetsuro Akashi, Toshinari Kimura, Hisato Igarashi, Takamasa Oono, Masayuki Furukawa, Ken Kawabe, Keiichiro Ogoshi, Jiro Oochi, Toshihiko Miyahara, Ryoichi Takayanagi, Tetsuhide Ito

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Aim: To evaluate the efficacy of continuous regional arterial infusion therapy (CRAI) with gabexate mesilate and antibiotics for severe acute pancreatitis (SAP). Methods: We conducted a prospective study on patients who developed SAP with or without CRAI. Out of 18 patients fulfilled clinical diagnostic criteria for SAP in Japan, 9 patients underwent CRAI, while 9 patients underwent conventional systemic protease inhibitor and antibiotics therapy (non-CRAI). CRAI was initiated within 72 h of the onset of pancreatitis. Gabexate mesilate (2400 mg/d) was continuously administered for 3 to 5 d. The clinical outcome including serum inflammation-related parameters were examined. Results: The duration of abdominal pain in the CRAI group was 1.9 ± 0.26 d, whereas that in the non-CRAI group was 4.3 ± 0.50. The duration of SIRS in the CRAI group was 2.2 ± 0.22 d, whereas that in the non-CRAI group was 3.2 ± 0.28. Abdominal pain and SIRS disappeared significantly in a short period of time after the initiation of CRAI using gabexate mesilate. The average length of hospitalization significantly differed between the CRAI and non-CRAI groups, 53.3 ± 7.9 d and 87.4 ± 13.9 d, respectively. During the first two weeks, levels of serum CRP and the IL6/IL10 ratio in the CRAI group tended to have a rapid decrease compared to those in the non-CRAI group. Conclusion: The present results suggest that CRAI using gabexate mesilate was effective against SAP.

Original languageEnglish
Pages (from-to)6382-6387
Number of pages6
JournalWorld Journal of Gastroenterology
Volume14
Issue number41
DOIs
Publication statusPublished - Nov 7 2008

Fingerprint

Gabexate
Intra Arterial Infusions
Pancreatitis
Group Psychotherapy
Therapeutics
Abdominal Pain
Anti-Bacterial Agents

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis. / Ino, Yoshifumi; Arita, Yoshiyuki; Akashi, Tetsuro; Kimura, Toshinari; Igarashi, Hisato; Oono, Takamasa; Furukawa, Masayuki; Kawabe, Ken; Ogoshi, Keiichiro; Oochi, Jiro; Miyahara, Toshihiko; Takayanagi, Ryoichi; Ito, Tetsuhide.

In: World Journal of Gastroenterology, Vol. 14, No. 41, 07.11.2008, p. 6382-6387.

Research output: Contribution to journalArticle

Ino, Y, Arita, Y, Akashi, T, Kimura, T, Igarashi, H, Oono, T, Furukawa, M, Kawabe, K, Ogoshi, K, Oochi, J, Miyahara, T, Takayanagi, R & Ito, T 2008, 'Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis', World Journal of Gastroenterology, vol. 14, no. 41, pp. 6382-6387. https://doi.org/10.3748/wjg.14.6382
Ino, Yoshifumi ; Arita, Yoshiyuki ; Akashi, Tetsuro ; Kimura, Toshinari ; Igarashi, Hisato ; Oono, Takamasa ; Furukawa, Masayuki ; Kawabe, Ken ; Ogoshi, Keiichiro ; Oochi, Jiro ; Miyahara, Toshihiko ; Takayanagi, Ryoichi ; Ito, Tetsuhide. / Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis. In: World Journal of Gastroenterology. 2008 ; Vol. 14, No. 41. pp. 6382-6387.
@article{81ee493fa86a477e9b5611b067f36b27,
title = "Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis",
abstract = "Aim: To evaluate the efficacy of continuous regional arterial infusion therapy (CRAI) with gabexate mesilate and antibiotics for severe acute pancreatitis (SAP). Methods: We conducted a prospective study on patients who developed SAP with or without CRAI. Out of 18 patients fulfilled clinical diagnostic criteria for SAP in Japan, 9 patients underwent CRAI, while 9 patients underwent conventional systemic protease inhibitor and antibiotics therapy (non-CRAI). CRAI was initiated within 72 h of the onset of pancreatitis. Gabexate mesilate (2400 mg/d) was continuously administered for 3 to 5 d. The clinical outcome including serum inflammation-related parameters were examined. Results: The duration of abdominal pain in the CRAI group was 1.9 ± 0.26 d, whereas that in the non-CRAI group was 4.3 ± 0.50. The duration of SIRS in the CRAI group was 2.2 ± 0.22 d, whereas that in the non-CRAI group was 3.2 ± 0.28. Abdominal pain and SIRS disappeared significantly in a short period of time after the initiation of CRAI using gabexate mesilate. The average length of hospitalization significantly differed between the CRAI and non-CRAI groups, 53.3 ± 7.9 d and 87.4 ± 13.9 d, respectively. During the first two weeks, levels of serum CRP and the IL6/IL10 ratio in the CRAI group tended to have a rapid decrease compared to those in the non-CRAI group. Conclusion: The present results suggest that CRAI using gabexate mesilate was effective against SAP.",
author = "Yoshifumi Ino and Yoshiyuki Arita and Tetsuro Akashi and Toshinari Kimura and Hisato Igarashi and Takamasa Oono and Masayuki Furukawa and Ken Kawabe and Keiichiro Ogoshi and Jiro Oochi and Toshihiko Miyahara and Ryoichi Takayanagi and Tetsuhide Ito",
year = "2008",
month = "11",
day = "7",
doi = "10.3748/wjg.14.6382",
language = "English",
volume = "14",
pages = "6382--6387",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "41",

}

TY - JOUR

T1 - Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis

AU - Ino, Yoshifumi

AU - Arita, Yoshiyuki

AU - Akashi, Tetsuro

AU - Kimura, Toshinari

AU - Igarashi, Hisato

AU - Oono, Takamasa

AU - Furukawa, Masayuki

AU - Kawabe, Ken

AU - Ogoshi, Keiichiro

AU - Oochi, Jiro

AU - Miyahara, Toshihiko

AU - Takayanagi, Ryoichi

AU - Ito, Tetsuhide

PY - 2008/11/7

Y1 - 2008/11/7

N2 - Aim: To evaluate the efficacy of continuous regional arterial infusion therapy (CRAI) with gabexate mesilate and antibiotics for severe acute pancreatitis (SAP). Methods: We conducted a prospective study on patients who developed SAP with or without CRAI. Out of 18 patients fulfilled clinical diagnostic criteria for SAP in Japan, 9 patients underwent CRAI, while 9 patients underwent conventional systemic protease inhibitor and antibiotics therapy (non-CRAI). CRAI was initiated within 72 h of the onset of pancreatitis. Gabexate mesilate (2400 mg/d) was continuously administered for 3 to 5 d. The clinical outcome including serum inflammation-related parameters were examined. Results: The duration of abdominal pain in the CRAI group was 1.9 ± 0.26 d, whereas that in the non-CRAI group was 4.3 ± 0.50. The duration of SIRS in the CRAI group was 2.2 ± 0.22 d, whereas that in the non-CRAI group was 3.2 ± 0.28. Abdominal pain and SIRS disappeared significantly in a short period of time after the initiation of CRAI using gabexate mesilate. The average length of hospitalization significantly differed between the CRAI and non-CRAI groups, 53.3 ± 7.9 d and 87.4 ± 13.9 d, respectively. During the first two weeks, levels of serum CRP and the IL6/IL10 ratio in the CRAI group tended to have a rapid decrease compared to those in the non-CRAI group. Conclusion: The present results suggest that CRAI using gabexate mesilate was effective against SAP.

AB - Aim: To evaluate the efficacy of continuous regional arterial infusion therapy (CRAI) with gabexate mesilate and antibiotics for severe acute pancreatitis (SAP). Methods: We conducted a prospective study on patients who developed SAP with or without CRAI. Out of 18 patients fulfilled clinical diagnostic criteria for SAP in Japan, 9 patients underwent CRAI, while 9 patients underwent conventional systemic protease inhibitor and antibiotics therapy (non-CRAI). CRAI was initiated within 72 h of the onset of pancreatitis. Gabexate mesilate (2400 mg/d) was continuously administered for 3 to 5 d. The clinical outcome including serum inflammation-related parameters were examined. Results: The duration of abdominal pain in the CRAI group was 1.9 ± 0.26 d, whereas that in the non-CRAI group was 4.3 ± 0.50. The duration of SIRS in the CRAI group was 2.2 ± 0.22 d, whereas that in the non-CRAI group was 3.2 ± 0.28. Abdominal pain and SIRS disappeared significantly in a short period of time after the initiation of CRAI using gabexate mesilate. The average length of hospitalization significantly differed between the CRAI and non-CRAI groups, 53.3 ± 7.9 d and 87.4 ± 13.9 d, respectively. During the first two weeks, levels of serum CRP and the IL6/IL10 ratio in the CRAI group tended to have a rapid decrease compared to those in the non-CRAI group. Conclusion: The present results suggest that CRAI using gabexate mesilate was effective against SAP.

UR - http://www.scopus.com/inward/record.url?scp=63449140185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449140185&partnerID=8YFLogxK

U2 - 10.3748/wjg.14.6382

DO - 10.3748/wjg.14.6382

M3 - Article

C2 - 19009656

AN - SCOPUS:63449140185

VL - 14

SP - 6382

EP - 6387

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 41

ER -